0001667699-22-000002.txt : 20220729 0001667699-22-000002.hdr.sgml : 20220729 20220729165233 ACCESSION NUMBER: 0001667699-22-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220729 DATE AS OF CHANGE: 20220729 EFFECTIVENESS DATE: 20220729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Renibus Therapeutics, Inc. CENTRAL INDEX KEY: 0001667699 IRS NUMBER: 810872431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-454246 FILM NUMBER: 221121588 BUSINESS ADDRESS: STREET 1: 950 E. STATE HIGHWAY 114 STREET 2: STE-160 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: 386-527-1071 MAIL ADDRESS: STREET 1: 950 E. STATE HIGHWAY 114 STREET 2: STE-160 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D 1 primary_doc.xml X0708 D LIVE 0001667699 Renibus Therapeutics, Inc. 181 Grand Avenue Suite 225 SOUTHLAKE TX TEXAS 76092 817.722.5768 DELAWARE None None Corporation true Carlos Guillem 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Director D. Jeffrey Keyser 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Director President, Secretary and Chief Operating Officer Henrik Rasmussen 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Director Bhupinder Singh 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Chief Medical Officer Frank Stonebanks 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Chief Executive Officer and Chairman of the Board Jamie Donadio 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Chief Financial Officer Pharmaceuticals Decline to Disclose 06b false 2022-07-15 false true true true Simple Agreement for Future Equity ("SAFE") false 0 Melior Capital Management GMBH None None None Baarerstrasse 12 Zug V8 SWITZERLAND 6300 true 20000000 14926102 5073898 false 17 12000 0 0 false Renibus Therapeutics, Inc. /s/ Frank Stonebanks Frank Stonebanks Chief Executive Officer and Chairman of the Board 2022-07-29